Basic information

2020/2892(RSP) RSP - Resolutions on topical subjects	Procedure completed
Resolution on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87427 × MON 89034 × MIR162 × MON 87411 and genetically modified maize combining two or three of the single events MON 87427, MON 89034, MIR162 and MON 87411 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council **Subject** 3.10.09.06 Agro-genetics, GMOs	

Key events

Date	Event	Reference	Summary
17/12/2020	Decision by Parliament	T9-0366/2020	Summary
17/12/2020	Results of vote in Parliament		

Technical information

Procedure reference	2020/2892(RSP)
Procedure type	RSP - Resolutions on topical subjects
Procedure subtype	Resolution on implementing act or powers
Legal basis	Rules of Procedure EP 115-p2
Stage reached in procedure	Procedure completed
Committee dossier	ENVI/9/04706

Documentation gateway

European Parliament

Document type	Committee	Reference	Date	Summary
Motion for a resolution		B9-0413/2020	14/12/2020	
Text adopted by Parliament, single reading		T9-0366/2020	17/12/2020	Summary

European Commission

Document type	Reference	Date	Summary
Commission response to text adopted in plenary	SP(2021)190	18/06/2021	

Resolution on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87427 × MON 89034 × MIR162 × MON 87411 and genetically modified maize combining two or three of the single events MON 87427, MON 89034, MIR162 and MON 87411 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council

2020/2892(RSP) - 17/12/2020 - Text adopted by Parliament, single reading

The European Parliament adopted by 488 votes to 186, with 32 abstentions, a resolution objecting to the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87427 × MON 89034 × MIR162 × MON 87411 and genetically modified maize combining two or three of the single events MON 87427, MON 89034, MIR162 and MON 87411 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council.

The application for marketing authorisation was submitted to the competent authorities of the Netherlands on 24 May 2017 by Monsanto Europe N.V. a, on behalf of Monsanto (USA). On 26 September 2019, the European Food Safety Authority (EFSA) adopted a favourable opinion on the application.

Main concerns from Member States

Members pointed out that Member States have submitted many critical comments to the EFSA, including that:

- no analysis has been done regarding glyphosate residues or glyphosate metabolites on the stacked GM soybean, that there has been no testing of the possible synergistic or antagonistic effects of the Bt toxins with the herbicide residues;

- questions on the safety of the stacked GM soybean and derived food and feed remain unanswered;

- the potential long-term reproductive or developmental effects of the food or feed have not been assessed and that, due to missing information, the safety of the stacked GM soybean cannot be fully assessed.

In addition, an independent scientific analysis concluded that no final conclusion can be drawn regarding the safety of the stacked GM soybean, that the toxicological assessment and the environmental risk assessment are unacceptable and that the risk assessment does not fulfil requirements for assessing risks to the immune system.

Complementary herbicides and lack of residue analysis

Members pointed out that the cultivation of herbicide-tolerant GM crops results in a higher use of herbicides, which is due in large part to the emergence of herbicide-tolerant weeds. It is therefore to be expected that crops of the GM maize will be exposed to both higher and repeated doses of glyphosate, which will potentially lead to a higher quantity of residues in the harvest.

In addition, there are still questions about the carcinogenicity of glyphosate. In 2015, the International Agency for Research on Cancer of the World Health Organization has, contrary to the EFSA and the European Chemicals Agency (ECHA), classified glyphosate as probably carcinogenic to humans.

Members also noted that side-effects have been observed which may affect the immune system following exposure to Bt proteins and that some Bt proteins may have adjuvant properties, meaning that they can increase the allergenicity of other proteins that they come into contact with.

Undemocratic decision-making

Members recalled that the vote in October 2020 of the Standing Committee on the Food Chain and Animal Health delivered no opinion, meaning that the authorisation was not supported by a qualified majority of Member States.

The Commission recognised that the fact that GMO authorisation decisions continue to be adopted by the Commission without a qualified majority of Member States in favour, which is very much the exception for product authorisations as a whole but which has become the norm for decision-making on GM food and feed authorisations, is problematic.

Recommendations

On the basis of these considerations, Parliament considered that the Commission's implementing decision is not consistent EU law. Consequently, it called on the Commission to:

- withdraw its draft implementing decision;

- move forward with the utmost urgency concerning the development of sustainability criteria, with full involvement of Parliament;

- take into account the EU’s obligations under international agreements, such as the Paris Climate Agreement, the UN Convention on Biological Diversity and the UN sustainable development goals;

- stop authorising GMOs, whether for cultivation or for food and feed uses, when no opinion is delivered by Member States in the Appeal Committee;

- not to authorise herbicide-tolerant GM crops until the health risks associated with the residues have been comprehensively investigated on a case-by-case basis;

- not to authorise any sub-combinations of stacked GM events unless they have been thoroughly evaluated by EFSA on the basis of complete data submitted by the applicant.

The EFSA is called on to further develop and systematically use methods that permit the identification of unintended effects of stacked GM events, such as in relation to the adjuvant properties of Bt proteins.